Q3 2022

Filed Nov 2, 2022 · 10-Q · 33 days after period end · 0001091818-22-000145

Q3 2022 · 10-Q

Revenue—

Net Income

-$122.59K

N/M vs Q3 2021

EPS Diluted

$0.00

— vs Q3 2021

Operating Cash Flowderived-$16,393N/M

Same quarter

Metric	Q3 2022	Q3 2021	Q3 2020	Q3 2019
Revenue	—	—	—	$5.96K
Net Income	-$122.59K	-$113.86K	-$117.92K	-$6.33K
EPS Diluted	$0.00	$0.00	-$0.01	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioforce Nanosciences Holdings, Inc. · CIK 1310488 · Engraved from SEC EDGAR